InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic agents)- Market Outlook And Industry Analysis 2034
The global Gastroesophageal Reflux Disease Therapeutics market is estimated to reach over USD 5.9 billion by 2034, exhibiting a CAGR of 1.9% during the forecast period.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1705
The market is anticipated to increase throughout the analysis period due to the rising prevalence of gastric reflux illnesses, changing lifestyles, and rising awareness of GERD. For instance, according to the National Library of Medicine’s article “Gastroesophageal Reflux Disease,” which was updated in July 2022, GERD is one of the most common chronic gastrointestinal conditions that affects about 20% of people in western culture and is identified by the regurgitation of gastric contents into the esophagus.
Moreover, the market players’ development initiatives, such as product launches, acquisitions, mergers, and investments, are anticipated to accelerate market expansion. One such instance is the new heartburn and reflux center that Medical City Frisco opened in October 2021, making it the only facility in Collin and Dallas counties.
List of Prominent Players in the Gastroesophageal Reflux Disease Therapeutics Market:
- AstraZeneca;
- Aurobindo Pharma Limited
- Cadila Pharmaceuticals Limited
- Camber Pharmaceuticals Inc.
- CHEPLAPHARM Arzneimittel GmbH
- Daewoong Pharmaceutical Co., Ltd
- Eisai Co. Ltd.
- EndoStim, Inc.
- GlaxoSmithKline PLC
- Ironwood Pharmaceuticals, Inc.;
- Jeil Pharmaceutical Co., Ltd.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Phathom Pharmaceuticals Inc.
- Reckitt Benckiser Group PLC
- Sebela Pharmaceuticals
- SFJ Pharmaceuticals Group
- SRS Life Sciences Pte. Ltd.
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceuticals Industries Limited
Market Dynamics:
Drivers-
TIF (transoral incisionless fundoplication) is used to treat GERD. TIF can lead to a shorter treatment period, less pain, and a quicker recovery than laparoscopic surgery. Using a specific TIF device, a path is created for an endoscope, a flexible, tube-like imaging instrument. Using preloaded tweezers and fasteners, the procedure enables the doctor to fix or replace the valve, a natural barrier to reflux. Clinical trials are currently being carried out to evaluate the effectiveness of endoscopic therapy for GERD.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/1705
Challenges:
Even though everything is working in the market’s favour, there are certain inescapable limitations, including patient mortality and a lackluster treatment pipeline. Due to the abundance of treatments available on the market for treating symptoms, there is the fierce rivalry.
Regional Trends:
North America is expected to expand and take the lead throughout the projection period. The United States is leading the market among other nations in the region because of things like rising healthcare spending, expanding research and technological advancements, and rising rates of gastroesophageal reflux disease (GERD). Moreover, the main factor driving the US GERD market is the growing elderly population across the nation.
A surgical procedure named a laparoscopic Nissen fundoplication is used to treat GERD. With GERD becoming more common, surgery is becoming more necessary. GERD is a widespread disorder affecting many people today, albeit more prevalent in western nations, particularly the United States. According to a Nissen Fundoplication article that appeared in the National Library of Medicine in July 2022, GERD is the condition with the highest prevalence in the country, affecting 18.1% to 27.8% of people. Given the disease’s significant prevalence there, it is expected that the presence and development of cutting-edge and potent medications will be necessary for the nation. Driving the nation’s market growth in the process.
Recent Developments:
- In June 2022, The Food and Drug Administration (FDA) permitted Zydus Lifesciences to market Famotidine tablets in strengths of 20mg and 40mg. Famotidine is a histamine H2 receptor blocker that functions by reducing stomach acid. The medication also prevents and treats heartburn and other acid indigestion symptoms.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customization/1705
Segmentation of Gastroesophageal Reflux Disease Therapeutics Market-
By Drug Type-
- Antacids
- H2 Receptor Blockers
- Proton Pump Inhibitors (PPIs)
- Pro-kinetic agents
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More Information :@
https://www.insightaceanalytic.com/report/gastroesophageal-reflux-disease-therapeutics-market/1705
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
Source: PR News Releaser
